VIFN.SW - Vifor Pharma AG

Swiss - Swiss Delayed Price. Currency in CHF
157.00
-1.15 (-0.73%)
At close: 5:30PM CET
Stock chart is not supported by your current browser
Previous Close158.15
Open158.30
Bid154.00 x 0
Ask160.00 x 0
Day's Range155.85 - 159.40
52 Week Range101.80 - 164.70
Volume199,689
Avg. Volume163,323
Market Cap10.301B
Beta (3Y Monthly)0.70
PE Ratio (TTM)103.02
EPS (TTM)1.52
Earnings DateAug 8, 2019
Forward Dividend & Yield2.00 (1.26%)
Ex-Dividend Date2019-05-10
1y Target Est163.00
  • Vifor Pharma and Evotec form joint venture for early development in nephrology
    Business Wire

    Vifor Pharma and Evotec form joint venture for early development in nephrology

    ST. GALLEN, Switzerland & HAMBURG, Germany-- -- Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics Collaboration brings together Evotec’s best-in-class drug discovery capabilities and Vifor Pharma’s development and commercialization expertise in nephrology Joint venture will focus on patient data driven target identification ...

  • Business Wire

    Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen

    ST GALLEN, Switzerland-- -- Agreement to jointly commercialise the new diabetic kidney disease indication for INVOKANA ® in the US Only diabetes treatment indicated to slow down the progression of DKD in type 2 diabetes patients since the standard of care was developed nearly 20 years ago, while also reducing the risk of heart failure hospitalizations Using its US salesforce to promote INVOKANA ® to ...

  • Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science
    Business Wire

    Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science

    Likewise, there is a lack of experts with the necessary specialist knowledge – and these experts are urgently needed in industry, at regulatory authorities and in medical practice, including in Switzerland. As with other areas of cutting-edge research, this will take the form of a global race: those able to present findings as quickly as possible will be able to assert themselves as a centre of excellence in nanopharmaceutics.

  • First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy
    Business Wire

    First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy

    Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2. Presently, RAASi treatment is frequently discontinued due to the risk of hyperkalaemia (elevated blood potassium levels).

  • Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
    Business Wire

    Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint

    ZURICH-- -- Veltassa ® enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190510005469/en/ Vifor Pharma today announced results from the phase-II AMBER study which demonstrated ...

  • Business Wire

    91st Vifor Pharma Group Annual Shareholder Meeting

    ZURICH-- -- Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Sue Mahony and Kim Stratton and to the Board of Directors Confirmation of all members of the Board of Directors standing for re-election Dividend of CHF 2.00 approved Regulatory News: At the 91 st Annual Shareholder Meeting of Vifor Pharma Ltd., shareholders approved all proposed ...

  • Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
    Business Wire

    Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement

    The Vifor Pharma Group (VIFN.VX) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their license agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a license to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.